Pathway-Guided Deep Neural Network toward Interpretable and Predictive Modeling of Drug Sensitivity
Open accessPublished version of a preprint
Abstract
To efficiently save cost and reduce risk in drug research and development, there is a pressing demand to develop in silico methods to predict drug sensitivity to cancer cells. With the exponentially increasing number of multi-omics data derived from high-throughput techniques, machine learning-based methods have been applied to the prediction of drug sensitivities. However, these methods have drawbacks either in the interpretability of the mechanism of drug action or limited performance in modeling drug sensitivity. In this paper, we presented a pathway-guided deep neural network (DNN) model to predict the drug sensitivity in cancer cells. Biological pathways describe a group of molecules in a cell that collaborates to control various biological functions like cell proliferation and death, thereby abnormal function of pathways can result in disease. To take advantage of the excellent predictive ability of DNN and the biological knowledge of pathways, we reshaped the canonical DNN structure by incorporating a layer of pathway nodes and their connections to input gene nodes, which makes the DNN model more interpretable and predictive compared to canonical DNN. We have conducted extensive performance evaluations on multiple independent drug sensitivity data sets and demonstrated that our model significantly outperformed the canonical DNN model and eight other classical regression models. Most importantly, we observed a remarkable activity decrease in disease-related pathway nodes during forward propagation upon inputs of drug targets, which implicitly corresponds to the inhibition effect of disease-related pathways induced by drug treatment on cancer cells. Our empirical experiments showed that our method achieves pharmacological interpretability and predictive ability in modeling drug sensitivity in cancer cells. The web server, the processed data sets, and source codes for reproducing our work are available at http://pathdnn.denglab.org.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Even with a simple growth inhibition readout, genes and pathways that determine drug response can be identified.
“Even with such a simple readout, genes and pathways that determine drug response can be identified,199,200”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [200]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 42 · Cited by 71
Research works printed but not linked: 1
- D. G. Savage and K. H. Antman, "Imatinib mesylatexa new oral targeted therapy.," New England Journal of Medicine, vol. 346, no. 9, pp. 683-693, 2002.
- Authors
- Deng, L., Cai, Y., Zhang, W., Yang, W., Gao, B., & Liu, H.
- Affiliations
- Central South University (CN)
- Changzhou University (CN)
- Changzhou No.2 People's Hospital (CN)
- Corresponding author
- Gao, Bo
- Liu, Hui
- Venue
- Journal of Chemical Information and Modeling
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-08-17
- Volume
- 60
- Issue
- 10
- Pages
- 4497-4505
- ISSN
- 1549-9596 (ISSN-L)
- 1549-960X
- OpenAlex
- W3074545577
- Cited by
- 71
- References
- 42
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 13 · 2023: 14 · 2022: 9 · 2021: 8
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- Journal of Chemical Information and Modeling (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (61672113, 61672541)
- Topics
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Machine Learning in Bioinformatics
- Keywords
- drug response prediction, cancer cells, biological pathways, interpretability, therapeutic target, pathway inhibition, multi-omics data
- MeSH terms
- Machine Learning, Pharmaceutical Preparations, Neural Networks, Computer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review